Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies

Condition(s)
Leukemia Lymphoma

Age Group
0-9 years 10-17 years 18-26 years

Phase(s)
1

Biological treatment cell Biological
CD22 CAR
Trial Summary

Background:
One type of cancer therapy takes blood cells from a person, changes them in a lab, then gives the cells back to the person. In this study, researchers are using an anti-CD22 gene, a virus, and an immune receptor to change the cells.

Objective:
To see if giving anti-CD22 Chimeric Antigen Receptor (CAR) cells to young people with certain cancers is safe and effective.

Eligibility:
People ages 1-30 with a leukemia or lymphoma that has not been cured by standard therapy.

Ages: 1 Year to 30 Years
Condition: Follicular Lymphoma, ALL, NHL, Large Cell Lymphoma
Status
Recruiting
Location(s)
National Institutes of Health (NIH) Clinical Center, Bethesda, MD
Contact
Lauren Little
240-858-3536